1.1700
-0.0200
(-1.68%)
At close: 4:00:00 PM EST
1.2400
+0.07
+(5.98%)
After hours: 5:42:32 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
--
--
--
--
10,006.0000
Operating Expense
44,594.0000
31,109.0000
28,239.0000
27,816.0000
24,161.0000
Operating Income
-44,594.0000
-31,109.0000
-28,239.0000
-27,816.0000
-14,155.0000
Net Non Operating Interest Income Expense
2,967.0000
1,073.0000
-83.0000
9.0000
-1,575.0000
Pretax Income
-41,627.0000
-30,036.0000
-28,322.0000
-27,807.0000
-15,730.0000
Tax Provision
1.0000
1.0000
1.0000
1.0000
--
Net Income Common Stockholders
-41,628.0000
-30,037.0000
-28,323.0000
-27,808.0000
-15,730.0000
Diluted NI Available to Com Stockholders
-41,628.0000
-30,037.0000
-28,323.0000
-27,808.0000
-15,730.0000
Basic EPS
-1.02
-1.58
-1.86
-3.20
-4.50
Diluted EPS
-1.02
-1.58
-1.86
-3.20
-4.50
Basic Average Shares
45,013.4310
18,960.4010
15,259.9580
8,570.4530
3,497.7370
Diluted Average Shares
45,013.4310
18,960.4010
15,259.9580
8,570.4530
3,497.7370
Total Operating Income as Reported
-44,594.0000
-31,109.0000
-28,239.0000
-27,816.0000
-14,155.0000
Total Expenses
44,594.0000
31,109.0000
28,239.0000
27,816.0000
24,161.0000
Net Income from Continuing & Discontinued Operation
-41,628.0000
-30,037.0000
-28,323.0000
-27,808.0000
-15,730.0000
Normalized Income
-41,628.0000
-30,037.0000
-28,323.0000
-27,808.0000
-15,730.0000
Interest Income
3,226.0000
1,677.0000
605.0000
864.0000
233.0000
Interest Expense
259.0000
604.0000
688.0000
855.0000
1,808.0000
Net Interest Income
2,967.0000
1,073.0000
-83.0000
9.0000
-1,575.0000
EBIT
-41,368.0000
-29,432.0000
-27,634.0000
-26,952.0000
-13,922.0000
EBITDA
-41,032.0000
-29,205.0000
-27,512.0000
-26,493.0000
-13,455.0000
Reconciled Depreciation
336.0000
227.0000
122.0000
459.0000
467.0000
Net Income from Continuing Operation Net Minority Interest
-41,628.0000
-30,037.0000
-28,323.0000
-27,808.0000
-15,730.0000
Normalized EBITDA
-41,032.0000
-29,205.0000
-27,512.0000
-26,493.0000
-13,455.0000
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0003
--
12/31/2020 - 10/9/2012
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
VTYX Ventyx Biosciences, Inc.
2.0200
-1.46%
STOK Stoke Therapeutics, Inc.
9.82
-7.10%
INZY Inozyme Pharma, Inc.
1.5200
+11.76%
PASG Passage Bio, Inc.
0.5764
-6.00%
AVTX Avalo Therapeutics, Inc.
8.04
+12.29%
ARTL Artelo Biosciences, Inc.
1.1900
+1.71%
GOSS Gossamer Bio, Inc.
0.9208
+0.77%
UNCY Unicycive Therapeutics, Inc.
0.5390
-5.44%
SABS SAB Biotherapeutics, Inc.
2.0700
-52.52%
BPTH Bio-Path Holdings, Inc.
0.8370
+1.57%